Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Empagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms SHIELD
Most Recent Events
- 19 Feb 2025 Status changed from not yet recruiting to recruiting.
- 11 Nov 2024 Planned End Date changed from 31 Dec 2028 to 1 Feb 2028.
- 11 Nov 2024 Planned primary completion date changed from 31 Dec 2028 to 1 Jan 2028.